Abstract:Factors associated with the atherosclerotic process, including inflammation, senescence-associated secretory phenotypes and telomere dysfunction are closely linked to senescence in VSMCs. However, whether senescent VSMCs are sufficient to cause atherosclerotic process and whether the phenotypes and risk factors of senescent VSMCs affect atherosclerotic pathogenesis are unclear. We investigated the mechanism of inhibition of atherosclerosis by the anti-aging agent metformin and whether attenuating risk factors senescent VSMCs affects atherogenesis. We performed in vitro studies including western blot, immunoprecipitation, RT-PCR, flow cytometry, immunofluorescence, FISH analysis, MMP zymography, and transfection of TERT siRNA. In vivo, to test the effect metformin on atherosclerotic lesion formation in ApoE-/- mice, male mice were divided into three groups (each, n = 5). After feeding the high-fat diet for 16 weeks, mice were sacrificed and the formation of atherosclerotic lesions in the aortas and the aortic sinuses were analyzed. Oleic acid (OA)-induced atherosclerotic pathogenesis in normal VSMCs showed marked senescence-associated features, manifested as increased b-gal positive cells and phenotypic switching of VSMCs in vitro; however, these phenomena were shown to be reversed by metformin. To determine what mechanism by metformin alleviates atherogenesis and senescent VSMC, we studied in the enhancement of telomere function by phosphorylating AMPK (Ser485) and PGC1 alpha. In our results, metformin showed increased the expression of p-AMPK (Ser485) as well as the phosphorylation of PGC1 alpha-dependent TERT expression and telomerase activity. Importantly, the depletion of TERT did not reduce risk factors for atherosclerosis and aged VSMCs despites metformin treatment in OA-induced atherosclerotic pathogenesis. We also found in the aortas of high-fat diet ApoE-/- mice, metformin treatment significantly attenuated atherosclerotic plaques and senescent VSMCs, and upregulated the expression of p-AMPK (Ser485)/p-PGC1 alpha and the enhancement of telomere function. The reduction of atherosclerotic pathogenesis in VSMCs and ApoE-/- mice is associated with significantly inhibited senescent phenotypes and risk factors. Increasing p-AMPK (Ser485)/p-PGC1 alpha by metformin the enhancement of telomere function mitigates senescent risk factors and may be a promising therapeutic strategy in atherosclerosis.

Τhe Endless Beauty of Metformin: Does It Also Protect from Skin Aging? A Narrative Review

A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan

The anti-aging role of metformin, clinical applications to pursue the longevity road

Modulation of autophagy, apoptosis and oxidative stress: a clue for repurposing metformin in photoaging

Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms

Metformin: From diabetes to cancer to prolongation of life

Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?

Metformin: An Old Drug with New Applications

Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation

Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity

New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway

Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.

228-LB: Metformin Alleviates Aging-Associated Metabolic Disorders through Intestinal AMPK-Mediated Gut Microbiome Alteration

Delaying Renal Aging: Metformin Holds Promise As a Potential Treatment

Metformin, lipids and atherosclerosis prevention

Obligatory Role of AMPK Activation and Antioxidant Defense Pathway in the Regulatory Effects of Metformin on Cellular Protection and Prevention of Lens Opacity

Repurposing metformin: an old drug with new tricks in its binding pockets

STABILIZATION OF TELOMERE BY THE ANTI-AGING PROPERTY OF METFORMIN MITIGATES OLEIC ACID-INDUCED ATHEROSCLEROTIC PATHOGENESIS

Metformin alleviates human cellular aging by upregulating the endoplasmic reticulum glutathione peroxidase 7

Metformin prevents murine ovarian aging

Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium